Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 19/20 | 0.73 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.73 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19714256 | 1.00 | PTGER4 (0.73) | PTGER4PTGER2PTGDRLMNA | |
| SCHEMBL692172 | 0.93 | PTGER4 (0.70) | PTGER4PTGER2PTGDR | |
| SCHEMBL5188816 | 0.93 | PTGER4 (0.70) | PTGER4PTGER2PTGDR | |
| SCHEMBL15463550 | 0.92 | PTGER4 (0.61) | PTGER4PTGER2LMNA | |
| SCHEMBL3984102 | 0.92 | PTGER4 (0.61) | PTGER4PTGER2LMNA | |
| SCHEMBL19713764 | 0.91 | PTGER4 (0.63) | PTGER4PTGER2PTGDR | |
| SCHEMBL691363 | 0.91 | PTGER4 (0.63) | PTGER4PTGER2PTGDR | |
| SCHEMBL26914668 | 0.90 | PTGER4 (0.71) | PTGER4PTGER2PTGDR | |
| SCHEMBL692242 | 0.90 | PTGER4 (0.71) | PTGER4PTGER2PTGDR | |
| SCHEMBL22076482 | 0.90 | PTGER4 (0.61) | PTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253595-A1 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | ASKAT INC. (JP) | 2017-09-07 | — | — | US | claimed |
| US-20160317514-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2016-11-03 | — | — | US | claimed |
| EP-2976105-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | AskAt Inc. (JP) | 2016-01-27 | — | — | EP | claimed |
| WO-2014148053-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2014-09-25 | — | — | WO | claimed |
| EP-1756042-B1 | SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS | RAQUALIA PHARMA INC (JP) | 2014-02-12 | — | — | EP | claimed |
| EP-2538978-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RaQualia Pharma Inc (JP) | 2013-01-02 | — | — | EP | claimed |
| US-20120316197-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2012-12-13 | — | — | US | claimed |
| US-20120088723-A1 | SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | RAQUALIA PHARMA INC. (JP) | 2012-04-12 | — | — | US | claimed |
| EP-2422779-A1 | SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | RaQualia Pharma Inc (JP) | 2012-02-29 | — | — | EP | claimed |
| WO-2011102149-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2011-08-25 | — | — | WO | claimed |
| US-20090163558-A1 | Substituted Methyl Aryl or Heteroaryl Amide Compounds | RAQUALIA PHARMA INC. (JP) | 2009-06-25 | — | — | US | claimed |
| US-7534914-B2 | Substituted methyl aryl or heteroaryl amide compounds | REQUALIA PHARMA INC. (JP) | 2009-05-19 | — | — | US | claimed |
| EP-1756042-A1 | SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS | Pfizer, Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| US-20050267170-A1 | Substituted methyl aryl or heteroaryl amide compounds | PFIZER INC | 2005-12-01 | — | — | US | claimed |
| WO-2005105732-A1 | SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2005-11-10 | — | — | WO | claimed |
| US-11840530-B2 | Selective EP4 receptor antagonistic substance for treatment of cancer | ASKAT INC. (JP) | 2023-12-12 | — | — | US | disclosed |
| EP-2976105-B1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC (JP) | 2023-01-04 | — | — | EP | disclosed |
| WO-2005105732-A1 | SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316197-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | PTGER4, PTGER3, IL23R | PTGER4 1/4885PTGER2 6/4885PTGDR 15/4885 |
| US-20170253595-A1 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885PTGDR 7/4885 |
| US-11840530-B2 | Selective EP4 receptor antagonistic substance for treatment of cancer | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885PTGDR 7/4885 |
| US-20120088723-A1 | SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885PTGDR 7/4885 |
| US-20160317514-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885PTGDR 11/4885 |
| US-20090163558-A1 | Substituted Methyl Aryl or Heteroaryl Amide Compounds | PTGER1, PTGER2, PTGER3 | PTGER4 14/4885PTGER2 2/4885PTGDR 15/4885 |
| US-20050267170-A1 | Substituted methyl aryl or heteroaryl amide compounds | PTGER1, PTGER2, PTGER3 | PTGER4 14/4885PTGER2 2/4885PTGDR 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.